advertisement
Abstract #61021 Published in IGR 17-1
The Effect of Rebamipide on Ocular Surface Disorders Induced by Latanoprost and Timolol in Glaucoma Patients
Tokuda N; Kitaoka Y; Matsuzawa A; Miyamoto J; Sakae S; Munemasa Y; Takagi HJournal of Ophthalmology 2015; 2015: 689076
PURPOSE: To examine the efficacy of ophthalmic rebamipide suspensions on ocular surface disorders induced by antiglaucoma eye drops. PATIENTS AND METHODS: Forty eyes of 40 patients receiving latanoprost (0.005%) and timolol (0.5%) were included in this randomized prospective study. The patients were randomly divided into two groups (n = 20): the rebamipide-treated group and control group. Changes in intraocular pressure, tear film break-up time (TBUT), and corneal epithelial barrier function were evaluated at baseline, 4 weeks, and 8 weeks after rebamipide administration. Furthermore, superficial punctate keratopathy severity was evaluated by scoring the lesion area and density. RESULTS: There was no significant difference in intraocular pressure before and after rebamipide treatment. However, corneal epithelial barrier function improved significantly 4 and 8 weeks after rebamipide treatment. TBUT was partially, but significantly, increased (P = 0.02) 8 weeks after rebamipide treatment, whereas no significant change was observed at 4 weeks. Additionally, a significant decrease in area and density of keratopathy was observed 8 weeks after rebamipide treatment but not at 4 weeks. The control group showed no significant difference compared to baseline. CONCLUSIONS: Our data suggests that rebamipide treatment may reduce the occurrence of drug-induced ocular surface disorder.
Department of Ophthalmology, St. Marianna University School of Medicine, Kanagawa 216-8511, Japan.
Full articleClassification:
11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)
2.1 Conjunctiva (Part of: 2 Anatomical structures in glaucoma)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)
